We are proud to share that Global Health & Pharma (GHP) has awarded Patent Medical AG the title “Leaders in Dental Technology Innovation 2026.”
This recognition is a testament to the mission that has guided us from the start: making tooth replacement better.
In its Q2 print edition, the magazine spoke with our CEO and founder, Marco Waldner, about Patent™ Symbionic Teeth and the remarkable benefits they bring to patients with tooth loss.
The breakthrough lies in the soft tissue
Around a healthy natural tooth, the soft tissue is firmly attached to the tooth neck, protecting the surrounding tissue – including the jawbone – from plaque. When a tooth is lost, this protection is lost with it.
Dental implants are not designed to restore this protection: while they integrate into the bone (osseointegration), they typically keep their distance from the soft tissue. This leaves an open pathway between the implant surface and the soft tissue that leads deep into the peri-implant tissue. Plaque can enter through this pathway and trigger tissue inflammation (mucositis), which becomes chronic once it reaches the bone (peri-implantitis). According to a literature review, roughly two-thirds of implant patients suffer from tissue inflammation.
Patent™ Symbionic Teeth are engineered to restore the protective mechanism of a lost tooth. They osseointegrate like dental implants do – but they go a significant step further:
The soft tissue bonds with their transmucosal surface. The result of this process is a mucosal defense barrier that can keep plaque away from the bone. This technological achievement positions symbionic teeth as a major advancement over dental implants.
By honoring us with this prestigious award, GHP is recognizing our role as innovation pioneers in the dental industry – and Patent™ Symbionic Teeth as a breakthrough technology that advances what is possible in tooth replacement.
What the long-term studies show
Researchers have documented the mucosal defense barrier of symbionic teeth in histological analyses. Its clinical effect in keeping plaque away from the bone is reflected in the results of two independent clinical long-term studies, conducted at the University of Düsseldorf and in collaboration with the Medical University of Graz (Brunello 2022; Karapataki 2023).
Both studies reported 0% peri-implantitis. In addition, the Düsseldorf study reported a mean probing depth of 3.0 mm across the entire cohort of Patent™ Symbionic Teeth investigated – a value that corresponds to the definition of a healthy natural tooth. The same study also documented long-term esthetic results: although the plaque index increased over time, mean recession for the cohort remained unchanged between the 2- and 9-year evaluations, at just 0.1 mm.
The Graz study, meanwhile, reported largely healthy soft tissue – even in patients with risk factors.
Commenting on these findings, Marco Waldner says: “This technology demonstrates that we do not have to accept that a replacement tooth performs worse by default than a natural tooth.”
Patients at the center
According to Waldner, Patent Medical AG’s goal is simple: patients worldwide should receive the best possible replacement for their missing teeth – a solution that can offer long-term esthetics by supporting healthy soft tissue and reducing the risk of chronic inflammation.
At Patent Medical AG, we see this award as recognition of the dentists and researchers who work with us every day – and as encouragement for our entire team to keep going.
Want to learn more?
Are you looking for a tooth replacement solution that can offer your patients true, long-term treatment results? Contact Patent Medical AG to learn more about Patent™ Symbionic Teeth and how their mucosal defense barrier can benefit your patients.
About Global Health & Pharma
Global Health & Pharma (GHP) is an established international media brand serving professionals across the healthcare and pharmaceutical industries. For more than a decade, GHP has reported on the news, innovations and developments shaping the sector, and has become a trusted source of in-depth analysis and exclusive content. Its quarterly digital magazine reaches a highly engaged global subscriber base and has profiled hundreds of industry leaders and innovators. GHP's Healthcare & Pharmaceutical Awards recognise organisations that set the standard for excellence and innovation in their field.